Loading…
Loading…
German drugs packaging firm Gerresheimer said on Wednesday it was selling two of its packaging units to private equity group Apax Funds for €1.5 billion ($1.71 billion) including debt.
Gerresheimer ETR: GXI said it has completed a broad review of compliance and accounting matters, published its audited 2025 annual report and is now focused on selling Centor, refinancing debt and improving cash generation.
German medical packaging maker Gerresheimer has rejected a takeover bid from its U.S. rival Silgan , three sources familiar with the situation told Reuters.
Gerresheimer on Tuesday again deferred the release of 2025 financial statements to June, citing a probe into its business deals, a delay that is now set to cost the German medical products maker its place on the Deutsche Boerse's SDAX index.
Diamond Hill International Strategy returned 3.87% (net of fees) and the MSCI ACWI ex USA Index returned 5.05%. Sumitomo Densetsu, a Japanese electrical contractor, benefited from a takeover bid by Daiwa House, whose tender offer at a premium price drove the stock higher. Stock selection in information technology and industrials contributed, along with our overweight to communication services.
Medical equipment maker Gerresheimer said on Tuesday it had appointed Uwe Röhrhoff as interim CEO, effective November 1, 2025. He succeeds Dietmar Siemssen, who will step down as CEO by mutual agreement with the company's supervisory board on October 31.
Medical equipment maker Gerresheimer said it has obtained the initial findings from an investigation by an external law firm into the recognition of revenue and profit from bill-and-hold agreements in the 2024 financial year.
Gerresheimer AG (OTCPK:GRRMY) Q3 2025 Earnings Call October 9, 2025 2:30 AM EDT Company Participants Guido Pickert - Head of Investor Relations Dietmar Siemssen - CEO, Chairman of the Management Board and CEO of Plastics, Devices & Advanced Technologies Division Wolf Lehmann - CFO & Member of the Management Board Conference Call Participants Edward Hall - Stifel, Nicolaus & Company, Incorporated, Research Division Olivier Calvet - UBS Investment Bank, Research Division David Adlington - JPMorgan Chase & Co, Research Division Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division Presentation Guido Pickert Head of Investor Relations Good morning, everyone, and welcome to our presentation of our preliminary Q3 2025 results. With us today are our CEO, Dietmar Siemssen; and our new CFO, Wolf Lehmann, who will lead you through our Q3 development and the financials.
No recent filings indexed.